GLPwatch

Activation of GLP-1 Receptor Promotes Bone Marrow Stromal Cell Osteogenic Differentiation through β-Catenin.

Stem Cell Reports · 2016

Last updated 2026-05-28

In a rat study, the GLP-1 drug exendin-4 (Ex-4) increased bone formation, bone mass, and bone quality while reducing fat cells in bone marrow. The drug worked by activating a receptor found in bone marrow stromal cells (not in bone-forming cells) and triggered two specific signaling pathways to promote bone cell development.

AI summary of the abstract below.

JournalStem Cell Reports, 2016
Citations104
Relative citation ratio4.34
NIH percentile91
Molecules

Abstract

Glucagon-like peptide 1 (GLP-1) plays an important role in regulating bone remodeling, and GLP-1 receptor agonist shows a positive relationship with osteoblast activity. However, GLP-1 receptor is not found in osteoblast, and the mechanism of GLP-1 receptor agonist on regulating bone remodeling is unclear. Here, we show that the GLP-1 receptor agonist exendin-4 (Ex-4) promoted bone formation and increased bone mass and quality in a rat unloading-induced bone loss model. These functions were accompanied by an increase in osteoblast number and serum bone formation markers, while the adipocyte number was decreased. Furthermore, GLP-1 receptor was detected in bone marrow stromal cells (BMSCs), but not in osteoblast. Activation of GLP-1 receptor by Ex-4 promoted the osteogenic differentiation and inhibited BMSC adipogenic differentiation through regulating PKA/β-catenin and PKA/PI3K/AKT/GSK3β signaling. These findings reveal that GLP-1 receptor regulates BMSC osteogenic differentiation and provide a molecular basis for therapeutic potential of GLP-1 against osteoporosis.

Verbatim abstract via PubMed 26947974 ↗